SDZ 220-581 is an orally bioavailable, potent, and competitive NMDA receptor antagonist (pKi = 7.7) used to protect against maximal electroshock seizures (MES) in mice in a dose-dependent manner following oral administration; it exhibits a rapid onset and long duration of action.